Yuichi Iwaki, Founder, President, and Chief Executive Officer, MediciNova
Dr. Yuichi Iwaki is a founder, president and CEO of Medicinova, Inc, a biopharmaceutical company which is public both in the JASDAQ (code 4875) and NASDAQ (code MNOV) market. Dr. Iwaki also holds three professorships at the University of Southern California, Keck School of Medicine in the Departments of Urology, Surgery and Pathology and has been Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992. He is also a visiting professor at the Toho University School of Medicine, St. Mary University and Kyushu University in Japan. Prior to joining the faculty at the University of Southern California, Keck School of Medicine, Dr. Iwaki held professorships at the University of Pittsburgh, School of Medicine in the Departments of Surgery and Pathology from 1989 through 1992. He received both his M.D. and Ph.D. degrees from Sapporo Medical School Japan. Dr. Iwaki is the author of more than 230 peer-reviewed publications and more than 40 books or book chapters. He has been advising pharmaceutical companies and venture capital funds regarding research and investment strategies for over 30 years and is a board member of several biotechnology companies.
Bo Liu, PhD, Principal, Venture Investments, Johnson & Johnson Innovation – JJDC, Inc. (JJDC)
Bo is the Principal of Venture Investments of Johnson & Johnson Innovation – JJDC, Inc. (JJDC). He is based in Shanghai, China and focuses on the life science investment opportunities in Asia Pacific regions. Prior to joining JJDC, Bo was Director of Business Development and Strategic Planning with GlaxoSmithKline Consumer Healthcare China, where he led key strategic initiatives in mergers and acquisitions, licensing and portfolio optimization. Prior to GSK, he worked in the corporate development and strategy group with Charles River Laboratories in Boston, where he played an instrumental role in several strategic transactions. Bo has executed many M&A, licensing and venture investment transactions in the US, Europe and Asia Pacific. Bo received a PhD in Pharmacology from University of Rochester, an MBA from the University of Chicago, and a Master of Medicine from the seven-year program of Tongji Medical University in Wuhan, China. He received residency training in Urology at Union Hospital of Tongji Medical University.
Ellen Lubman, Vice President, External Science & Innovation, Allergan PLC
Ellen came to Allergan after joining predecessor company, Forest Laboratories, in February 2014 as Vice President, Strategy and Innovation Ellen's mandate is to bring novel initiatives, products and opportunities to Allergan’s pipeline and increase the company's access to scientific and structural innovation in defined areas of therapeutic expertise. Ellen has 15+ years of experience throughout the biopharmaceutical industry. Ellen started her career as a pharmaceutical representative with Abbott Laboratories then joined investment banking firm, Robertson Stephens, as a Biotechnology equity research analyst during the height of the genomics revolution, focused on early stage drug discovery and development companies. After completing her MBA from Stanford Graduate School of Business with a focus on Global Management, Ellen joined as a founding member of a biotechnology private equity fund, Celtic Pharma. Ellen has worked with venture capital funds, seed-stage, biotech and pharma companies, in business and corporate development, operations and strategy roles, including Amgen, Kadmon Corporation and Bristol-Myers Squibb where she was instrumental in executing on the "String of Pearls" targeted growth strategy.
Arlene Morris, Chief Executive Officer, Willow Advisors
Ms. Morris is currently the CEO of Willow Advisors, a consultancy advising biotech companies on financing, strategy and business development. Previously she was the CEO and Director of Syndax an oncology/immunoncology company developing entinostat for estrogen receptor positive metastatic breast cancer and lung cancer as well as melanoma. Under her leadership the compound advanced to a Phase 3 NCI sponsored study in combination with exemestane to reverse resistance to hormone therapy in patients. The compound was awarded Breakthrough Status by the FDA. Previously she was the chief executive officer and member of the board of directors for Affymax, Inc., a biopharmaceutical company located in Palo Alto, Calif., which was spun out of GlaxoSmithKline (GSK) in 2001 to develop a pipeline of synthetic peptide-based drug candidates including treatment of anemia in dialysis patients. During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of OMONTYS peginesatide, a strategic collaboration with Takeda and an Initial Public Offering and several follow on offerings. Prior to Affymax, Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counsels biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president of business development at Coulter, a biotech company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter. Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development. In addition to Syndax, Ms. Morris serves on the board of directors of Neovacs SA, Palatin, Biodel and Dimension Therapeutics. She also serves on the board of the Foundation for Research and Development at the Medical University of South Carolina. She was recently on the boards of the Humane Society of Silicon Valley and BIO.
Kyle Murphy, Managing Director and Founder, KMG Japan
Kyle E. Murphy is the Managing Director and Founder of KMG Japan. Kyle has lived in Japan for a significant portion of his adult life. His business has involved working with Japanese and Asian Life Science and healthcare businesses for over 30 years. Kyle speaks Japanese and built a strong network of contacts in both the healthcare industry and government administration. He has represented over 100 clients and successfully structured numerous alliances between Japanese, Asian and foreign companies. Prior to founding KMG Japan, Kyle served as the First Commercial Secretary in the US Embassy in Tokyo where he managed all trade negotiations and activities related to bringing US companies into the Japanese healthcare market. Kyle began his career in the healthcare industry with business development and marketing positions at Schering-Plough in Osaka, Japan and SmithKline in the US.
Charles Stacey, MD, Chief Executive Officer, Accera
Dr. Stacey has over 15 years of experience in healthcare; working as a healthcare provider, executive, entrepreneur and investor. Prior to joining Accera, he was with Inventages, a global healthcare venture capital and private equity group. Dr. Stacey received his medical degree from King’s College London and practiced as a reconstructive surgeon. His undergraduate degree and basic research were in the neurosciences at University College London. Dr. Stacey also completed an MBA at the London Business School and the Wharton School.
Ted Tanaka, Partnering Consultant, Tanaka International LLC
Ted Tanaka has worked at Accenture, where he managed teams of Accenture consultants and client staff to design and install improved management information systems for major US and Japan clients (including Yamaha & Ricoh). After 11 years, Los Angeles’ Consulting Division had grown to 170 consultants. In 1986, Accenture, he created Tanaka International, an industry leading Japan/Asia specialist to clients in the USA, Canada, UK and Australia which aims to form corporate strategic alliances. He has personally arranged and conducted more than 2,500 strategic alliance and licensing meetings for clients at the global headquarters of Japan’s largest drug manufacturers. He maintains personal, direct contact with Japanese CEOs, board of directors and global licensing heads, and has assisted clients to sign 23 license agreements to-date in Japan and Korea.
Gil Van Bokkelen, PhD, Chairman & Chief Executive Officer, Athersys
Dr. Van Bokkelen has served as the Chief Executive Officer and Chairman since August 2000. Dr. Van Bokkelen co-founded Athersys in 1995 and has served as Chief Executive Officer and Director since the Company’s founding. Prior to May 2006, he also served as the Company’s President. Dr. Van Bokkelen is also the Chairman of the Board of Governors for the National Center for Regenerative Medicine. He served as the Chairman of the Alliance for Regenerative Medicine from 2010 through 2012, a Washington D.C. based consortium of companies, patient advocacy groups, disease foundations, and clinical and research institutions that are committed to the advancement of the field of regenerative medicine, and served ex officio from 2013 to 2014. He has served on a number of other boards, including the Biotechnology Industry Organization’s ECS board of directors (from 2001 to 2004, and from 2008 to present). He received his Ph.D. in Genetics from Stanford University School of Medicine, his B.A. in Economics from the University of California at Berkeley, and his B.A. in Molecular Biology from the University of California at Berkeley. Dr. Van Bokkelen brings to the Board leadership, extensive business, operating, financial and scientific experience, and tremendous knowledge of our Company and the biotechnology industry. Dr. Van Bokkelen also brings his broad strategic vision for the Company to the Board of Directors and his service as the Chairman and Chief Executive Officer of Athersys creates a critical link between management and the Board, enabling the Board to perform its oversight function with the benefit of management’s perspectives on the business. In addition, having the Chief Executive Officer, and Dr. Van Bokkelen, in particular, on the Board of Directors provides the Company with ethical, decisive and effective leadership.